What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi as part of the treatment landscape?

What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi as part of the treatment landscape?

What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi that are or will be part of the treatment landscape?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium